Eight Capital Lowers MedReleaf (LEAF) to Tender

Eight Capital lowered shares of MedReleaf (TSE:LEAF) from a buy rating to a tender rating in a report issued on Tuesday morning.

Several other equities research analysts have also recently commented on the company. Cormark cut MedReleaf from a buy rating to a tender rating in a report on Tuesday. Beacon Securities reaffirmed a buy rating and issued a C$29.00 price target on shares of MedReleaf in a report on Tuesday, May 8th. Finally, Canaccord Genuity increased their price objective on MedReleaf from C$21.50 to C$30.00 and gave the stock a buy rating in a research report on Wednesday, February 14th.

TSE:LEAF opened at C$22.28 on Tuesday. MedReleaf has a one year low of C$6.81 and a one year high of C$31.25.

In other MedReleaf news, insider Eitan Popper acquired 27,500 shares of the stock in a transaction that occurred on Tuesday, March 27th. The stock was bought at an average cost of C$18.09 per share, for a total transaction of C$497,475.00. Also, insider Ray Leach sold 19,600 shares of the stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of C$19.00, for a total value of C$372,400.00. Insiders sold 338,900 shares of company stock valued at $6,485,612 over the last quarter.

MedReleaf Company Profile

MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.

Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply